T-Cell Activation Profile, CD8 Subsets

T-Cell Activation Profile, CD8 Subsets

Number

505750

CPT

86356 (x3); 86359; 86360

Test Includes

Percentage and absolute values CD3⁺, CD3⁺CD4⁺, CD3⁺CD8⁺, CD3⁺CD25⁺, CD8⁺CD38⁺, CD8⁺HLA-DR⁺, CD4:CD8 ratio; CBC with differential

Special Instructions

State date and time of collection on the request form and on the specimen tube.

Specimen

Whole blood

Volume

7 mL EDTA whole blood and 7 mL ACD-A whole blood

Container

Lavender-top (EDTA) tube and yellow-top (ACD-A) tube

Collection

To preserve cellular viability, collect specimen so it will arrive in the laboratory Monday through Friday and within 24 hours of collection. Please indicate date and time of venipuncture on the tube(s) and on the request form.

Storage Instructions

Maintain specimen at room temperature. Do not freeze or refrigerate.

Causes for Rejection

Hemolysis; specimen refrigerated or frozen; clotted specimen; contaminated specimen

Reference Interval

Reference intervals are established by the laboratory. See table. Adult Reference Intervals for Lymphocyte Immunophenotyping

CD	95% Confidence Interval
	Percentage		Cells/mm³
	Minimum	Maximum	Minimum	Maximum
CD3⁺	58	86	622	2402
CD3⁺CD4⁺	31	59	359	1519
CD3⁺CD8⁺	12	36	109	897
CD3⁺CD25⁺	5	26	79	535
T4:T8 ratio	0.92	3.72
CD8⁺CD38⁺	0	18	0	381
CD8⁺HLA-DR⁺	0	5	0	117

Use

Expanded profile for AIDS monitoring and prognosis. An increase in activation markers is associated with poor prognosis.

Limitations

This procedure may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients.

Methodology

Flow cytometry

References

Landay AL, Jessop C, Lennette ET, et al, “Chronic Fatigue Syndrome: Clinical Condition Associated With Immune Activation,” Lancet, 1991, 338(8769):707-12.

Sadler D and Keren DF, “Surface Marker Assays in Immunodeficiency Diseases,” Flow Cytometry and Clinical Diseases, Chapter 9, Keren DF, Hanson CA, and Hurtubise PE, eds, Chicago, IL: ASCP Press, 1994.